Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 2 4

Status

Recruiting 5Not yet recruiting 2Active not recruiting 1

Sponsor Class

INDUSTRY 6OTHER 1NIH 1

Study Type

Interventional 8

Sponsor

Cancer Type

Thoracic 7Sarcoma 1

Conditions

Small Cell Lung Carcinoma 6Lung Neoplasms 2Neoplasms 1Leiomyosarcoma 1Extensive Stage Small Cell Lung Cancer (ES-SCLC) 1Carcinoma, Small Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Specimen Handling 278Magnetic Resonance Spectroscopy 233pembrolizumab 227Carboplatin 187Cisplatin 153Biopsy 148Cyclophosphamide 143Paclitaxel 133Nivolumab 122Gemcitabine 113Bevacizumab 104Radiotherapy 92Dexamethasone 86Pemetrexed 83fludarabine 77Fluorouracil 76Docetaxel 75Doxorubicin 74atezolizumab 71Radiation 71Leucovorin 70Rituximab 67Oxaliplatin 66venetoclax 61durvalumab 61Prednisone 60Vincristine 56Cetuximab 56Lenalidomide 54Etoposide 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

8 trials
RecentStart dateEnrollment
Interventional × PM 01183 × 30 days × Clear all
NCT06228066 2026-06-05

Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
45 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT07625644 2026-06-04

Evaluate BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer

SystImmune Inc.

Phase 3 Not yet recruiting
550 enrolled
Thoracic

Lung Neoplasms, Carcinoma, Small Cell, Small Cell Lung Carcinoma

NCT06203210 2026-06-02

IDeate-Lung02

Daiichi Sankyo

Phase 3 Recruiting
540 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT07459634 2026-05-27

A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC

Jazz Pharmaceuticals

Phase 2 Not yet recruiting
50 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT05800587 2026-05-22

Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer

Fox Chase Cancer Center

Phase 2 Recruiting
280 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Small Cell Lung Carcinoma

NCT06801834 2026-05-20

EVOKE-SCLC-04

Gilead Sciences

Phase 3 Recruiting
695 enrolled
Thoracic

Extensive Stage Small Cell Lung Cancer (ES-SCLC)

NCT07155174 2026-05-18

SEZanne

AbbVie

Phase 2 Recruiting
180 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT06088290 2026-05-15

SaLuDo

PharmaMar

Phase 3 Active not recruiting
455 enrolled
Sarcoma

Leiomyosarcoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡